pharmaceuticals

pharmaceuticals Articles

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden Pharma DAC....
Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead. The company applied to list its common stock on The Nasdaq...
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Tonix Pharmaceuticals watched its shares take a handy jump early on Thursday, following positive results from its mid-stage PTSD study.
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Valeant Pharmaceuticals is trying to change its tune by announcing that it will offer an enhanced rebate program to all hospitals in the United States, in an effort to reduce the price of Nitropress...
Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more than $5 billion.
The Oncobiologics initial public offering suffered a devastating first day. Shares ended down 20%.
Parnell Pharmaceuticals Holdings saw its shares drop by over 10% early Thursday following the pricing of its secondary offering.
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
Anacor Pharmaceuticals reported its first-quarter financial results before the markets opened on Tuesday.
A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks, including these biotech and pharmaceutical picks.
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.